Thomas Gaziano
Harvard Medical School
Health Policy and Management
Harvard School of Public Health
Associate Physician in Cardiovascular Medicine
Department of Cardiology
Brigham & Women's Hospital
Co-Leader
Chronic & Cardiovascular Diseases Working Group
Harvard Institute for Global Health
Thomas Gaziano M.D., M.Sc. is jointly appointed to the Divisions of Cardiovascular Medicine and Social Medicine and Health Inequalities at Brigham & Women's Hospital, Harvard Medical School, and the Department of Health Policy and Management, Harvard School of Public Health. Dr. Gaziano is certified as a Diplomat in Internal Medicine and Cardiovascular Diseases and has expertise in the treatment of cardiovascular diseases (CVD) in developing countries including the epidemiology and management of its risk factors. His research includes the development of decision analytic models to assess the cost-effectiveness of various screening, prevention and management decisions--including in developing countries. Dr. Gaziano's international experience includes two years at Oxford University South Africa as the first Lancet International Fellow and recently four months in India evaluating CVD epidemiology and cost-effective strategies for its management. He has served as a consultant and author for the Disease Control Priorities Project organized by the World Bank, WHO, and the Fogarty International Center, NIH and has been funded by the Bill and Melinda Gates Foundation.
Chronic diseases are increasingly becoming a health burden in lowerand middle-income countries, putting pressure on public health efforts to scale up interventions. This article reviews current efforts in interventions on a population and individual level. Population-level interventions include ongoing efforts to reduce smoking rates, reduce intake of salt and trans-fatty acids, and increase physical activity in increasingly sedentary populations. Individual-level interventions include control and treatment of risk factors for chronic diseases and secondary prevention. This review also discusses the barriers in interventions, particularly those specific to low- and middle-income countries. Continued discussion of proven cost-effective interventions for chronic diseases in the developing world will be useful for improving public health policy. Expected final online publication date for the Annual Review of Public Health Volume 34 is March 17, 2013. Please see http://www.annualreviews.org/catalog/pubdates.aspx for revised estimates
Chronic diseases are increasingly becoming a health burden in lowerand middle-income countries, putting pressure on public health efforts to scale up interventions. This article reviews current efforts in interventions on a population and individu... (more »)
BACKGROUND:
National and international primary CVD risk screening guidelines focus on using total CVD risk scores. Recently, we developed a non-laboratory-based CVD risk score (inputs: age, sex, smoking, diabetes, systolic blood pressure, treatment of hypertension, body-mass index), which can assess risk faster and at lower costs compared to laboratory-based scores (inputs include cholesterol values). We aimed to assess the exchangeability of the non-laboratory-based risk score to four commonly used laboratory-based scores (Framingham CVD [2008, 1991 versions], and Systematic COronary Risk Evaluation [SCORE] for low and high risk settings) in an external validation population.
METHODS AND FINDINGS:
Analyses were based on individual-level, score-specific rankings of risk for adults in the Third National Health and Nutrition Examination Survey (NHANES III) aged 25-74 years, without history of CVD or cancer (n = 5,999). Risk characterization agreement was based on overlap in dichotomous risk characterization (thresholds of 10-year risk >10-20%) and Spearman rank correlation. Risk discrimination was assessed using receiver operator characteristic curve analysis (10-year CVD death outcome). Risk characterization agreement ranged from 91.9-95.7% and 94.2-95.1% with Spearman correlation ranges of 0.957-0.980 and 0.946-0.970 for men and women, respectively. In men, c-statistics for the non-laboratory-based, Framingham (2008, 1991), and SCORE (high, low) functions were 0.782, 0.776, 0.781, 0.785, and 0.785, with p-values for differences relative to the non-laboratory-based score of 0.44, 0.89, 0.68 and 0.65, respectively. In women, the corresponding c-statistics were 0.809, 0.834, 0.821, 0.792, and 0.792, with corresponding p-values of 0.04, 0.34, 0.11 and 0.09, respectively.
CONCLUSIONS:
Every score discriminated risk of CVD death well, and there was high agreement in risk characterization between non-laboratory-based and laboratory-based risk scores, which suggests that the non-laboratory-based score can be a useful proxy for Framingham or SCORE functions in resource-limited settings. Future external validation studies can assess whether the sex-specific risk discrimination results hold in other populations.
BACKGROUND:
National and international primary CVD risk screening guidelines focus on using total CVD risk scores. Recently, we developed a non-laboratory-based CVD risk score (inputs: age, sex, smoking, diabetes, systolic blood pre... (more »)
To estimate individual and household economic impact of cardiovascular disease (CVD) in selected low- and middle-income countries (LMIC).
BACKGROUND:
Empirical evidence on the microeconomic consequences of CVD in LMIC is scarce.
METHODS AND FINDINGS:
We surveyed 1,657 recently hospitalized CVD patients (66% male; mean age 55.8 years) from Argentina, China, India, and Tanzania to evaluate the microeconomic and functional/productivity impact of CVD hospitalization. Respondents were stratified into three income groups. Median out-of-pocket expenditures for CVD treatment over 15 month follow-up ranged from 354 international dollars (2007 INT$, Tanzania, low-income) to INT$2,917 (India, high-income). Catastrophic health spending (CHS) was present in >50% of respondents in China, India, and Tanzania. Distress financing (DF) and lost income were more common in low-income respondents. After adjustment, lack of health insurance was associated with CHS in Argentina (OR 4.73 [2.56, 8.76], India (OR 3.93 [2.23, 6.90], and Tanzania (OR 3.68 [1.86, 7.26] with a marginal association in China (OR 2.05 [0.82, 5.11]). These economic effects were accompanied by substantial decreases in individual functional health and productivity.
CONCLUSIONS:
Individuals in selected LMIC bear significant financial burdens following CVD hospitalization, yet with substantial variation across and within countries. Lack of insurance may drive much of the financial stress of CVD in LMIC patients and their families.
To estimate individual and household economic impact of cardiovascular disease (CVD) in selected low- and middle-income countries (LMIC).
BACKGROUND:
Empirical evidence on the microeconomic consequences of CVD in LMIC is scarce.<... (more »)
OBJECTIVE:
To estimate individual and household economic impact of cardiovascular disease (CVD) in selected low- and middle-income countries (LMIC).
BACKGROUND:
Empirical evidence on the microeconomic consequences of CVD in LMIC is scarce.
METHODS AND FINDINGS:
We surveyed 1,657 recently hospitalized CVD patients (66% male; mean age 55.8 years) from Argentina, China, India, and Tanzania to evaluate the microeconomic and functional/productivity impact of CVD hospitalization. Respondents were stratified into three income groups. Median out-of-pocket expenditures for CVD treatment over 15 month follow-up ranged from 354 international dollars (2007 INT$, Tanzania, low-income) to INT$2,917 (India, high-income). Catastrophic health spending (CHS) was present in >50% of respondents in China, India, and Tanzania. Distress financing (DF) and lost income were more common in low-income respondents. After adjustment, lack of health insurance was associated with CHS in Argentina (OR 4.73 [2.56, 8.76], India (OR 3.93 [2.23, 6.90], and Tanzania (OR 3.68 [1.86, 7.26] with a marginal association in China (OR 2.05 [0.82, 5.11]). These economic effects were accompanied by substantial decreases in individual functional health and productivity.
CONCLUSIONS:
Individuals in selected LMIC bear significant financial burdens following CVD hospitalization, yet with substantial variation across and within countries. Lack of insurance may drive much of the financial stress of CVD in LMIC patients and their families.
OBJECTIVE:
To estimate individual and household economic impact of cardiovascular disease (CVD) in selected low- and middle-income countries (LMIC).
BACKGROUND:
Empirical evidence on the microeconomic consequences of CVD... (more »)
Coronary heart disease (CHD) is the single largest cause of death in the developed countries and is one of the leading causes of disease burden in developing countries. In 2001, there were 7.3 million deaths due to CHD worldwide. Three-fourths of global deaths due to CHD occurred in the low- and middle-income countries. The rapid rise in CHD burden in most of the low- and middle-income countries is due to socio-economic changes, increase in lifespan, and acquisition of lifestyle-related risk factors. The CHD death rate, however, varies dramatically across the developing countries. The varying incidence, prevalence, and mortality rates reflect the different levels of risk factors, other competing causes of death, availability of resources to combat cardiovascular disease, and the stage of epidemiologic transition that each country or region finds itself. The economic burden of CHD is equally large but solutions exist to manage this growing burden.
Coronary heart disease (CHD) is the single largest cause of death in the developed countries and is one of the leading causes of disease burden in developing countries. In 2001, there were 7.3 million deaths due to CHD worldwide. Three-fourths ... (more »)
BACKGROUND: Patients with acute coronary syndrome (ACS) in India have increased pre-hospital delay and low rates of thrombolytic reperfusion. Use of ECG could reduce pre-hospital delay among patients who first present to a general practitioner (GP). We assessed whether performing ECG on patients with acute chest pain would improve long-term outcomes and be cost-effective. METHODS: We created a Markov model of urban Indian patients presenting to a GP with acute chest pain to compare a GP's performing an ECG versus not performing one. Variables describing the accuracy of a GP's referral decision in chest pain and ACS, ACS treatment patterns, the effectiveness of thrombolytic reperfusion, and costs were derived from Indian data where available and other developed world studies. The model was used to estimate the incremental cost-effectiveness ratio (ICER) of the intervention in 2007 US dollars per quality adjusted life years (QALY) gained. RESULTS: Under baseline assumptions, the ECG strategy cost an additional $12.65 per QALY gained compared to no ECG. Sensitivity analyses around the cost of the ECG, cost of thrombolytic, and referral accuracy of the GP yielded ICERs for the ECG strategy ranging between cost-saving and $1124/QALY. All results indicated the intervention is cost-effective under current World Health Organization recommendations. CONCLUSIONS: While direct presentation to the hospital with acute chest pain is preferable, in urban Indian patients presenting first to a GP, an ECG performed by the GP is a cost-effective strategy to reduce disability and mortality. This strategy should be clinically studied and considered until improved emergency transport services are available.
BACKGROUND: Patients with acute coronary syndrome (ACS) in India have increased pre-hospital delay and low rates of thrombolytic reperfusion. Use of ECG could reduce pre-hospital delay among patients who first present to a general practitioner ... (more »)
Cardiovascular disease (CVD) is the leading cause of mortality, responsible for about 30% of deaths worldwide. Globally, 80% of total CVD deaths occur in developing countries. In recent years, age-adjusted CVD death has been cut in half in developed countries. Much of the decline is due to reductions in risk factors that the Framingham Heart Study helped to identify. The Framingham Heart Study also helped to classify those at highest risk by creating multivariate risk scores. As a result, other investigators have created various risk prediction scores for their countries. These scores have been the foundation for guidelines and prevention strategies in developed countries. However, most scores requiring blood tests may be difficult to implement in developing countries where limited resources for screening exist. New studies and risk scores inspired by the Framingham Heart Study need to simplify risk scoring in developing countries so that affordable prevention strategies can be implemented.
Cardiovascular disease (CVD) is the leading cause of mortality, responsible for about 30% of deaths worldwide. Globally, 80% of total CVD deaths occur in developing countries. In recent years, age-adjusted CVD death has been cut in half in deve... (more »)
BACKGROUND: Patients with acute coronary syndrome (ACS) in India have increased pre-hospital delay and low rates of thrombolytic reperfusion. Use of ECG could reduce pre-hospital delay among patients who first present to a general practitioner (GP). We assessed whether performing ECG on patients with acute chest pain would improve long-term outcomes and be cost-effective.
METHODS: We created a Markov model of urban Indian patients presenting to a GP with acute chest pain to compare a GP's performing an ECG versus not performing one. Variables describing the accuracy of a GP's referral decision in chest pain and ACS, ACS treatment patterns, the effectiveness of thrombolytic reperfusion, and costs were derived from Indian data where available and other developed world studies. The model was used to estimate the incremental cost-effectiveness ratio (ICER) of the intervention in 2007 US dollars per quality adjusted life years (QALY) gained.
RESULTS: Under baseline assumptions, the ECG strategy cost an additional $12.65 per QALY gained compared to no ECG. Sensitivity analyses around the cost of the ECG, cost of thrombolytic, and referral accuracy of the GP yielded ICERs for the ECG strategy ranging between cost-saving and $1124/QALY. All results indicated the intervention is cost-effective under current World Health Organization recommendations.
CONCLUSIONS: While direct presentation to the hospital with acute chest pain is preferable, in urban Indian patients presenting first to a GP, an ECG performed by the GP is a cost-effective strategy to reduce disability and mortality. This strategy should be clinically studied and considered until improved emergency transport services are available.
BACKGROUND: Patients with acute coronary syndrome (ACS) in India have increased pre-hospital delay and low rates of thrombolytic reperfusion. Use of ECG could reduce pre-hospital delay among patients who first present to a ge... (more »)
The United States is not alone in facing increasing incidence and prevalence of chronic conditions as a contributor to poorer health and growing health care spending. Latin America and the Caribbean face similar burdens, but they have fewer resources with which to respond. Much remains to be done to cope with the emerging public health and fiscal threat posed by increases in chronic conditions. However, a set of studies sponsored by the Inter-American Development Bank bring good news on potentially cost-effective strategies to improve coverage and outcomes. They should help move the growing epidemic of chronic diseases in Latin America and the Caribbean to the forefront of health policy in the region.
The United States is not alone in facing increasing incidence and prevalence of chronic conditions as a contributor to poorer health and growing health care spending. Latin America and the Caribbean face similar burdens, but they have fewer res... (more »)
Harvard School of Public Health







